nodes	percent_of_prediction	percent_of_DWPC	metapath
Anastrozole—CYP3A4—Thiotepa—urinary bladder cancer	0.105	0.276	CbGbCtD
Anastrozole—CYP1A2—Fluorouracil—urinary bladder cancer	0.0654	0.171	CbGbCtD
Anastrozole—CYP2C9—Fluorouracil—urinary bladder cancer	0.0589	0.154	CbGbCtD
Anastrozole—CYP1A2—Etoposide—urinary bladder cancer	0.0545	0.143	CbGbCtD
Anastrozole—CYP2C9—Cisplatin—urinary bladder cancer	0.05	0.131	CbGbCtD
Anastrozole—CYP3A4—Etoposide—urinary bladder cancer	0.0286	0.0747	CbGbCtD
Anastrozole—CYP3A4—Doxorubicin—urinary bladder cancer	0.0195	0.051	CbGbCtD
Anastrozole—CYP1A2—Phase II conjugation—GSTZ1—urinary bladder cancer	0.000959	0.00697	CbGpPWpGaD
Anastrozole—CYP1A2—Phase II conjugation—GSTO2—urinary bladder cancer	0.000909	0.00661	CbGpPWpGaD
Anastrozole—CYP1A2—Phase II conjugation—NAT1—urinary bladder cancer	0.000909	0.00661	CbGpPWpGaD
Anastrozole—CYP1A2—Estrogen Receptor Pathway—ESR1—urinary bladder cancer	0.000892	0.00649	CbGpPWpGaD
Anastrozole—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000882	0.00641	CbGpPWpGaD
Anastrozole—CYP1A2—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000875	0.00637	CbGpPWpGaD
Anastrozole—CYP1A2—Phase II conjugation—UGT2B7—urinary bladder cancer	0.000831	0.00604	CbGpPWpGaD
Anastrozole—CYP1A2—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000824	0.00599	CbGpPWpGaD
Anastrozole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000785	0.00571	CbGpPWpGaD
Anastrozole—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000774	0.00563	CbGpPWpGaD
Anastrozole—CYP19A1—Biological oxidations—NAT2—urinary bladder cancer	0.00077	0.0056	CbGpPWpGaD
Anastrozole—CYP19A1—FSH signaling pathway—SRC—urinary bladder cancer	0.000763	0.00555	CbGpPWpGaD
Anastrozole—CYP19A1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00076	0.00552	CbGpPWpGaD
Anastrozole—CYP2C9—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000732	0.00532	CbGpPWpGaD
Anastrozole—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000676	0.00491	CbGpPWpGaD
Anastrozole—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.000669	0.00486	CbGpPWpGaD
Anastrozole—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	0.000656	0.00477	CbGpPWpGaD
Anastrozole—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000647	0.00471	CbGpPWpGaD
Anastrozole—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000636	0.00463	CbGpPWpGaD
Anastrozole—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000634	0.00461	CbGpPWpGaD
Anastrozole—CYP1A2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000626	0.00455	CbGpPWpGaD
Anastrozole—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	0.000622	0.00452	CbGpPWpGaD
Anastrozole—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	0.000622	0.00452	CbGpPWpGaD
Anastrozole—CYP19A1—Biological oxidations—HPGDS—urinary bladder cancer	0.000616	0.00448	CbGpPWpGaD
Anastrozole—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000614	0.00446	CbGpPWpGaD
Anastrozole—CYP19A1—Integrated Breast Cancer Pathway—TSC1—urinary bladder cancer	0.000609	0.00443	CbGpPWpGaD
Anastrozole—CYP19A1—Biological oxidations—GSTT1—urinary bladder cancer	0.000597	0.00434	CbGpPWpGaD
Anastrozole—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.000569	0.00414	CbGpPWpGaD
Anastrozole—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000561	0.00408	CbGpPWpGaD
Anastrozole—CYP1A2—Biological oxidations—GSTZ1—urinary bladder cancer	0.000561	0.00408	CbGpPWpGaD
Anastrozole—CYP1A2—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000553	0.00402	CbGpPWpGaD
Anastrozole—CYP1A2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.000539	0.00392	CbGpPWpGaD
Anastrozole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.000539	0.00392	CbGpPWpGaD
Anastrozole—CYP1A2—Biological oxidations—GSTO2—urinary bladder cancer	0.000532	0.00387	CbGpPWpGaD
Anastrozole—CYP1A2—Biological oxidations—NAT1—urinary bladder cancer	0.000532	0.00387	CbGpPWpGaD
Anastrozole—CYP1A2—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000524	0.00381	CbGpPWpGaD
Anastrozole—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.000512	0.00373	CbGpPWpGaD
Anastrozole—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000505	0.00367	CbGpPWpGaD
Anastrozole—CYP1A2—Phase II conjugation—NAT2—urinary bladder cancer	0.000498	0.00362	CbGpPWpGaD
Anastrozole—CYP1A2—Biological oxidations—UGT2B7—urinary bladder cancer	0.000486	0.00354	CbGpPWpGaD
Anastrozole—CYP1A2—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00048	0.00349	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000445	0.00323	CbGpPWpGaD
Anastrozole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000441	0.00321	CbGpPWpGaD
Anastrozole—CYP1A2—Biological oxidations—CYP4B1—urinary bladder cancer	0.000438	0.00318	CbGpPWpGaD
Anastrozole—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000433	0.00315	CbGpPWpGaD
Anastrozole—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000433	0.00315	CbGpPWpGaD
Anastrozole—CYP1A2—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000432	0.00314	CbGpPWpGaD
Anastrozole—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000427	0.0031	CbGpPWpGaD
Anastrozole—Bronchitis—Epirubicin—urinary bladder cancer	0.000424	0.000883	CcSEcCtD
Anastrozole—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000421	0.000878	CcSEcCtD
Anastrozole—Depression—Methotrexate—urinary bladder cancer	0.000419	0.000873	CcSEcCtD
Anastrozole—Pain—Cisplatin—urinary bladder cancer	0.000417	0.00087	CcSEcCtD
Anastrozole—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000416	0.000868	CcSEcCtD
Anastrozole—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000416	0.000867	CcSEcCtD
Anastrozole—CYP19A1—Biological oxidations—GSTP1—urinary bladder cancer	0.000414	0.00301	CbGpPWpGaD
Anastrozole—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000414	0.000863	CcSEcCtD
Anastrozole—Dizziness—Thiotepa—urinary bladder cancer	0.000412	0.000858	CcSEcCtD
Anastrozole—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.00041	0.00298	CbGpPWpGaD
Anastrozole—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.00041	0.00298	CbGpPWpGaD
Anastrozole—Urticaria—Fluorouracil—urinary bladder cancer	0.000409	0.000852	CcSEcCtD
Anastrozole—CYP19A1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000408	0.00297	CbGpPWpGaD
Anastrozole—Influenza—Doxorubicin—urinary bladder cancer	0.000408	0.00085	CcSEcCtD
Anastrozole—Dysphagia—Doxorubicin—urinary bladder cancer	0.000408	0.00085	CcSEcCtD
Anastrozole—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000407	0.000848	CcSEcCtD
Anastrozole—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000405	0.00294	CbGpPWpGaD
Anastrozole—Sweating—Methotrexate—urinary bladder cancer	0.000402	0.000839	CcSEcCtD
Anastrozole—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000402	0.000838	CcSEcCtD
Anastrozole—Paraesthesia—Etoposide—urinary bladder cancer	0.000401	0.000837	CcSEcCtD
Anastrozole—Weight increased—Epirubicin—urinary bladder cancer	0.000401	0.000836	CcSEcCtD
Anastrozole—Weight decreased—Epirubicin—urinary bladder cancer	0.000399	0.000831	CcSEcCtD
Anastrozole—Dyspnoea—Etoposide—urinary bladder cancer	0.000399	0.000831	CcSEcCtD
Anastrozole—CYP1A2—Phase II conjugation—HPGDS—urinary bladder cancer	0.000398	0.00289	CbGpPWpGaD
Anastrozole—Somnolence—Etoposide—urinary bladder cancer	0.000397	0.000828	CcSEcCtD
Anastrozole—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000397	0.000828	CcSEcCtD
Anastrozole—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000397	0.000828	CcSEcCtD
Anastrozole—Vomiting—Thiotepa—urinary bladder cancer	0.000396	0.000825	CcSEcCtD
Anastrozole—Rash—Thiotepa—urinary bladder cancer	0.000392	0.000818	CcSEcCtD
Anastrozole—Bronchitis—Doxorubicin—urinary bladder cancer	0.000392	0.000817	CcSEcCtD
Anastrozole—Dermatitis—Thiotepa—urinary bladder cancer	0.000392	0.000817	CcSEcCtD
Anastrozole—Headache—Thiotepa—urinary bladder cancer	0.00039	0.000813	CcSEcCtD
Anastrozole—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.00039	0.000812	CcSEcCtD
Anastrozole—Decreased appetite—Etoposide—urinary bladder cancer	0.000389	0.00081	CcSEcCtD
Anastrozole—CYP1A2—Phase II conjugation—GSTT1—urinary bladder cancer	0.000386	0.00281	CbGpPWpGaD
Anastrozole—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000386	0.000805	CcSEcCtD
Anastrozole—Body temperature increased—Cisplatin—urinary bladder cancer	0.000386	0.000804	CcSEcCtD
Anastrozole—Fatigue—Etoposide—urinary bladder cancer	0.000385	0.000803	CcSEcCtD
Anastrozole—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000385	0.000803	CcSEcCtD
Anastrozole—Jaundice—Epirubicin—urinary bladder cancer	0.000383	0.000798	CcSEcCtD
Anastrozole—Pain—Etoposide—urinary bladder cancer	0.000382	0.000797	CcSEcCtD
Anastrozole—Constipation—Etoposide—urinary bladder cancer	0.000382	0.000797	CcSEcCtD
Anastrozole—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000382	0.000796	CcSEcCtD
Anastrozole—CYP19A1—Biological oxidations—GSTM1—urinary bladder cancer	0.000381	0.00277	CbGpPWpGaD
Anastrozole—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000379	0.000791	CcSEcCtD
Anastrozole—Haemoglobin—Methotrexate—urinary bladder cancer	0.000379	0.00079	CcSEcCtD
Anastrozole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000377	0.00274	CbGpPWpGaD
Anastrozole—Hepatitis—Methotrexate—urinary bladder cancer	0.000377	0.000786	CcSEcCtD
Anastrozole—Haemorrhage—Methotrexate—urinary bladder cancer	0.000377	0.000786	CcSEcCtD
Anastrozole—Sweating—Epirubicin—urinary bladder cancer	0.000377	0.000785	CcSEcCtD
Anastrozole—Asthenia—Gemcitabine—urinary bladder cancer	0.000376	0.000783	CcSEcCtD
Anastrozole—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000375	0.00273	CbGpPWpGaD
Anastrozole—CYP19A1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000375	0.00273	CbGpPWpGaD
Anastrozole—Pharyngitis—Methotrexate—urinary bladder cancer	0.000374	0.00078	CcSEcCtD
Anastrozole—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000372	0.000775	CcSEcCtD
Anastrozole—Weight increased—Doxorubicin—urinary bladder cancer	0.000371	0.000774	CcSEcCtD
Anastrozole—Pruritus—Gemcitabine—urinary bladder cancer	0.00037	0.000772	CcSEcCtD
Anastrozole—CYP1A2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.00037	0.00269	CbGpPWpGaD
Anastrozole—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00037	0.00269	CbGpPWpGaD
Anastrozole—Nausea—Thiotepa—urinary bladder cancer	0.00037	0.000771	CcSEcCtD
Anastrozole—Weight decreased—Doxorubicin—urinary bladder cancer	0.000369	0.000769	CcSEcCtD
Anastrozole—Sinusitis—Epirubicin—urinary bladder cancer	0.000369	0.000768	CcSEcCtD
Anastrozole—Feeling abnormal—Etoposide—urinary bladder cancer	0.000368	0.000768	CcSEcCtD
Anastrozole—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000366	0.000762	CcSEcCtD
Anastrozole—Pruritus—Fluorouracil—urinary bladder cancer	0.000364	0.000759	CcSEcCtD
Anastrozole—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.00036	0.000751	CcSEcCtD
Anastrozole—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00036	0.000749	CcSEcCtD
Anastrozole—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000358	0.000747	CcSEcCtD
Anastrozole—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000356	0.000743	CcSEcCtD
Anastrozole—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000356	0.000743	CcSEcCtD
Anastrozole—Urticaria—Etoposide—urinary bladder cancer	0.000355	0.00074	CcSEcCtD
Anastrozole—Haemoglobin—Epirubicin—urinary bladder cancer	0.000354	0.000739	CcSEcCtD
Anastrozole—Jaundice—Doxorubicin—urinary bladder cancer	0.000354	0.000739	CcSEcCtD
Anastrozole—Rhinitis—Epirubicin—urinary bladder cancer	0.000354	0.000737	CcSEcCtD
Anastrozole—Abdominal pain—Etoposide—urinary bladder cancer	0.000353	0.000737	CcSEcCtD
Anastrozole—Body temperature increased—Etoposide—urinary bladder cancer	0.000353	0.000737	CcSEcCtD
Anastrozole—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000353	0.000737	CcSEcCtD
Anastrozole—Hepatitis—Epirubicin—urinary bladder cancer	0.000353	0.000735	CcSEcCtD
Anastrozole—Haemorrhage—Epirubicin—urinary bladder cancer	0.000353	0.000735	CcSEcCtD
Anastrozole—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000352	0.000734	CcSEcCtD
Anastrozole—Asthenia—Cisplatin—urinary bladder cancer	0.00035	0.00073	CcSEcCtD
Anastrozole—Pharyngitis—Epirubicin—urinary bladder cancer	0.00035	0.00073	CcSEcCtD
Anastrozole—Sweating—Doxorubicin—urinary bladder cancer	0.000349	0.000727	CcSEcCtD
Anastrozole—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000347	0.000724	CcSEcCtD
Anastrozole—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000344	0.000717	CcSEcCtD
Anastrozole—Sinusitis—Doxorubicin—urinary bladder cancer	0.000341	0.000711	CcSEcCtD
Anastrozole—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000341	0.00248	CbGpPWpGaD
Anastrozole—Dizziness—Fluorouracil—urinary bladder cancer	0.00034	0.00071	CcSEcCtD
Anastrozole—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000338	0.00246	CbGpPWpGaD
Anastrozole—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000336	0.00244	CbGpPWpGaD
Anastrozole—CYP19A1—Integrated Breast Cancer Pathway—ATM—urinary bladder cancer	0.000335	0.00243	CbGpPWpGaD
Anastrozole—Diarrhoea—Cisplatin—urinary bladder cancer	0.000334	0.000696	CcSEcCtD
Anastrozole—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000333	0.000695	CcSEcCtD
Anastrozole—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000333	0.00242	CbGpPWpGaD
Anastrozole—CYP19A1—Integrated Breast Cancer Pathway—CDK4—urinary bladder cancer	0.000333	0.00242	CbGpPWpGaD
Anastrozole—Alopecia—Methotrexate—urinary bladder cancer	0.000333	0.000694	CcSEcCtD
Anastrozole—Vomiting—Gemcitabine—urinary bladder cancer	0.000333	0.000694	CcSEcCtD
Anastrozole—CYP19A1—Integrated Breast Cancer Pathway—ESR1—urinary bladder cancer	0.000332	0.00241	CbGpPWpGaD
Anastrozole—Rash—Gemcitabine—urinary bladder cancer	0.00033	0.000688	CcSEcCtD
Anastrozole—Dermatitis—Gemcitabine—urinary bladder cancer	0.00033	0.000687	CcSEcCtD
Anastrozole—Hypersensitivity—Etoposide—urinary bladder cancer	0.000329	0.000687	CcSEcCtD
Anastrozole—Erythema—Methotrexate—urinary bladder cancer	0.000328	0.000684	CcSEcCtD
Anastrozole—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000328	0.000684	CcSEcCtD
Anastrozole—Headache—Gemcitabine—urinary bladder cancer	0.000328	0.000684	CcSEcCtD
Anastrozole—Vomiting—Fluorouracil—urinary bladder cancer	0.000327	0.000682	CcSEcCtD
Anastrozole—Rhinitis—Doxorubicin—urinary bladder cancer	0.000327	0.000682	CcSEcCtD
Anastrozole—Hepatitis—Doxorubicin—urinary bladder cancer	0.000326	0.00068	CcSEcCtD
Anastrozole—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000326	0.00068	CcSEcCtD
Anastrozole—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000325	0.00236	CbGpPWpGaD
Anastrozole—Rash—Fluorouracil—urinary bladder cancer	0.000325	0.000677	CcSEcCtD
Anastrozole—Dermatitis—Fluorouracil—urinary bladder cancer	0.000324	0.000676	CcSEcCtD
Anastrozole—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000324	0.000675	CcSEcCtD
Anastrozole—Headache—Fluorouracil—urinary bladder cancer	0.000322	0.000672	CcSEcCtD
Anastrozole—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000321	0.00067	CcSEcCtD
Anastrozole—Dysgeusia—Methotrexate—urinary bladder cancer	0.000321	0.00067	CcSEcCtD
Anastrozole—Asthenia—Etoposide—urinary bladder cancer	0.000321	0.000669	CcSEcCtD
Anastrozole—Back pain—Methotrexate—urinary bladder cancer	0.000317	0.000662	CcSEcCtD
Anastrozole—Pruritus—Etoposide—urinary bladder cancer	0.000316	0.000659	CcSEcCtD
Anastrozole—Alopecia—Epirubicin—urinary bladder cancer	0.000312	0.00065	CcSEcCtD
Anastrozole—Nausea—Gemcitabine—urinary bladder cancer	0.000311	0.000648	CcSEcCtD
Anastrozole—Vomiting—Cisplatin—urinary bladder cancer	0.00031	0.000647	CcSEcCtD
Anastrozole—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000309	0.000643	CcSEcCtD
Anastrozole—Rash—Cisplatin—urinary bladder cancer	0.000308	0.000641	CcSEcCtD
Anastrozole—Dermatitis—Cisplatin—urinary bladder cancer	0.000307	0.000641	CcSEcCtD
Anastrozole—Erythema—Epirubicin—urinary bladder cancer	0.000307	0.00064	CcSEcCtD
Anastrozole—Diarrhoea—Etoposide—urinary bladder cancer	0.000306	0.000638	CcSEcCtD
Anastrozole—Nausea—Fluorouracil—urinary bladder cancer	0.000306	0.000637	CcSEcCtD
Anastrozole—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000304	0.000635	CcSEcCtD
Anastrozole—Anaemia—Methotrexate—urinary bladder cancer	0.000303	0.000632	CcSEcCtD
Anastrozole—Tension—Epirubicin—urinary bladder cancer	0.000301	0.000628	CcSEcCtD
Anastrozole—Dysgeusia—Epirubicin—urinary bladder cancer	0.000301	0.000627	CcSEcCtD
Anastrozole—Nervousness—Epirubicin—urinary bladder cancer	0.000298	0.000622	CcSEcCtD
Anastrozole—Back pain—Epirubicin—urinary bladder cancer	0.000297	0.000619	CcSEcCtD
Anastrozole—Malaise—Methotrexate—urinary bladder cancer	0.000296	0.000617	CcSEcCtD
Anastrozole—Dizziness—Etoposide—urinary bladder cancer	0.000296	0.000616	CcSEcCtD
Anastrozole—Leukopenia—Methotrexate—urinary bladder cancer	0.000294	0.000612	CcSEcCtD
Anastrozole—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	0.000291	0.00212	CbGpPWpGaD
Anastrozole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000291	0.00212	CbGpPWpGaD
Anastrozole—Nausea—Cisplatin—urinary bladder cancer	0.00029	0.000604	CcSEcCtD
Anastrozole—CYP19A1—Integrated Breast Cancer Pathway—RB1—urinary bladder cancer	0.00029	0.00211	CbGpPWpGaD
Anastrozole—CYP19A1—Integrated Breast Cancer Pathway—CDH1—urinary bladder cancer	0.000289	0.0021	CbGpPWpGaD
Anastrozole—Alopecia—Doxorubicin—urinary bladder cancer	0.000288	0.000601	CcSEcCtD
Anastrozole—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000287	0.00209	CbGpPWpGaD
Anastrozole—Cough—Methotrexate—urinary bladder cancer	0.000286	0.000597	CcSEcCtD
Anastrozole—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000285	0.000594	CcSEcCtD
Anastrozole—Vomiting—Etoposide—urinary bladder cancer	0.000284	0.000593	CcSEcCtD
Anastrozole—Erythema—Doxorubicin—urinary bladder cancer	0.000284	0.000592	CcSEcCtD
Anastrozole—Anaemia—Epirubicin—urinary bladder cancer	0.000284	0.000592	CcSEcCtD
Anastrozole—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000283	0.00206	CbGpPWpGaD
Anastrozole—Rash—Etoposide—urinary bladder cancer	0.000282	0.000588	CcSEcCtD
Anastrozole—Dermatitis—Etoposide—urinary bladder cancer	0.000282	0.000587	CcSEcCtD
Anastrozole—Headache—Etoposide—urinary bladder cancer	0.00028	0.000584	CcSEcCtD
Anastrozole—Chest pain—Methotrexate—urinary bladder cancer	0.000279	0.000582	CcSEcCtD
Anastrozole—Myalgia—Methotrexate—urinary bladder cancer	0.000279	0.000582	CcSEcCtD
Anastrozole—Arthralgia—Methotrexate—urinary bladder cancer	0.000279	0.000582	CcSEcCtD
Anastrozole—Tension—Doxorubicin—urinary bladder cancer	0.000279	0.000581	CcSEcCtD
Anastrozole—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000278	0.00058	CcSEcCtD
Anastrozole—Malaise—Epirubicin—urinary bladder cancer	0.000277	0.000577	CcSEcCtD
Anastrozole—Discomfort—Methotrexate—urinary bladder cancer	0.000276	0.000575	CcSEcCtD
Anastrozole—Nervousness—Doxorubicin—urinary bladder cancer	0.000276	0.000575	CcSEcCtD
Anastrozole—Leukopenia—Epirubicin—urinary bladder cancer	0.000275	0.000573	CcSEcCtD
Anastrozole—Back pain—Doxorubicin—urinary bladder cancer	0.000275	0.000573	CcSEcCtD
Anastrozole—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000273	0.00198	CbGpPWpGaD
Anastrozole—Confusional state—Methotrexate—urinary bladder cancer	0.00027	0.000563	CcSEcCtD
Anastrozole—Cough—Epirubicin—urinary bladder cancer	0.000268	0.000559	CcSEcCtD
Anastrozole—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000268	0.000558	CcSEcCtD
Anastrozole—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.000268	0.00195	CbGpPWpGaD
Anastrozole—Infection—Methotrexate—urinary bladder cancer	0.000266	0.000555	CcSEcCtD
Anastrozole—Nausea—Etoposide—urinary bladder cancer	0.000266	0.000554	CcSEcCtD
Anastrozole—Hypertension—Epirubicin—urinary bladder cancer	0.000265	0.000553	CcSEcCtD
Anastrozole—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000264	0.00192	CbGpPWpGaD
Anastrozole—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000264	0.000549	CcSEcCtD
Anastrozole—Anaemia—Doxorubicin—urinary bladder cancer	0.000263	0.000547	CcSEcCtD
Anastrozole—Arthralgia—Epirubicin—urinary bladder cancer	0.000261	0.000545	CcSEcCtD
Anastrozole—Chest pain—Epirubicin—urinary bladder cancer	0.000261	0.000545	CcSEcCtD
Anastrozole—Myalgia—Epirubicin—urinary bladder cancer	0.000261	0.000545	CcSEcCtD
Anastrozole—Anxiety—Epirubicin—urinary bladder cancer	0.00026	0.000543	CcSEcCtD
Anastrozole—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000259	0.00054	CcSEcCtD
Anastrozole—Discomfort—Epirubicin—urinary bladder cancer	0.000258	0.000538	CcSEcCtD
Anastrozole—Malaise—Doxorubicin—urinary bladder cancer	0.000256	0.000534	CcSEcCtD
Anastrozole—Dry mouth—Epirubicin—urinary bladder cancer	0.000256	0.000533	CcSEcCtD
Anastrozole—Anorexia—Methotrexate—urinary bladder cancer	0.000255	0.000532	CcSEcCtD
Anastrozole—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000255	0.00185	CbGpPWpGaD
Anastrozole—Leukopenia—Doxorubicin—urinary bladder cancer	0.000254	0.00053	CcSEcCtD
Anastrozole—CYP19A1—Metabolism—GSTZ1—urinary bladder cancer	0.000254	0.00184	CbGpPWpGaD
Anastrozole—Confusional state—Epirubicin—urinary bladder cancer	0.000253	0.000527	CcSEcCtD
Anastrozole—Oedema—Epirubicin—urinary bladder cancer	0.000251	0.000522	CcSEcCtD
Anastrozole—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000251	0.000522	CcSEcCtD
Anastrozole—Infection—Epirubicin—urinary bladder cancer	0.000249	0.000519	CcSEcCtD
Anastrozole—Cough—Doxorubicin—urinary bladder cancer	0.000248	0.000517	CcSEcCtD
Anastrozole—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000246	0.00179	CbGpPWpGaD
Anastrozole—Hypertension—Doxorubicin—urinary bladder cancer	0.000245	0.000511	CcSEcCtD
Anastrozole—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000244	0.000509	CcSEcCtD
Anastrozole—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000242	0.000505	CcSEcCtD
Anastrozole—Insomnia—Methotrexate—urinary bladder cancer	0.000242	0.000505	CcSEcCtD
Anastrozole—Chest pain—Doxorubicin—urinary bladder cancer	0.000242	0.000504	CcSEcCtD
Anastrozole—Arthralgia—Doxorubicin—urinary bladder cancer	0.000242	0.000504	CcSEcCtD
Anastrozole—Myalgia—Doxorubicin—urinary bladder cancer	0.000242	0.000504	CcSEcCtD
Anastrozole—Anxiety—Doxorubicin—urinary bladder cancer	0.000241	0.000502	CcSEcCtD
Anastrozole—CYP19A1—Metabolism—GSTO2—urinary bladder cancer	0.00024	0.00175	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism—NAT1—urinary bladder cancer	0.00024	0.00175	CbGpPWpGaD
Anastrozole—Paraesthesia—Methotrexate—urinary bladder cancer	0.00024	0.000501	CcSEcCtD
Anastrozole—Discomfort—Doxorubicin—urinary bladder cancer	0.000239	0.000498	CcSEcCtD
Anastrozole—Anorexia—Epirubicin—urinary bladder cancer	0.000239	0.000498	CcSEcCtD
Anastrozole—Dyspnoea—Methotrexate—urinary bladder cancer	0.000239	0.000498	CcSEcCtD
Anastrozole—Somnolence—Methotrexate—urinary bladder cancer	0.000238	0.000496	CcSEcCtD
Anastrozole—Dry mouth—Doxorubicin—urinary bladder cancer	0.000237	0.000493	CcSEcCtD
Anastrozole—CYP19A1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000237	0.00172	CbGpPWpGaD
Anastrozole—Dyspepsia—Methotrexate—urinary bladder cancer	0.000236	0.000491	CcSEcCtD
Anastrozole—Confusional state—Doxorubicin—urinary bladder cancer	0.000234	0.000487	CcSEcCtD
Anastrozole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.000233	0.00169	CbGpPWpGaD
Anastrozole—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.000233	0.00169	CbGpPWpGaD
Anastrozole—Decreased appetite—Methotrexate—urinary bladder cancer	0.000233	0.000485	CcSEcCtD
Anastrozole—Oedema—Doxorubicin—urinary bladder cancer	0.000232	0.000483	CcSEcCtD
Anastrozole—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000232	0.000483	CcSEcCtD
Anastrozole—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000231	0.000482	CcSEcCtD
Anastrozole—Fatigue—Methotrexate—urinary bladder cancer	0.000231	0.000481	CcSEcCtD
Anastrozole—Infection—Doxorubicin—urinary bladder cancer	0.00023	0.00048	CcSEcCtD
Anastrozole—Pain—Methotrexate—urinary bladder cancer	0.000229	0.000477	CcSEcCtD
Anastrozole—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000228	0.000476	CcSEcCtD
Anastrozole—Insomnia—Epirubicin—urinary bladder cancer	0.000227	0.000472	CcSEcCtD
Anastrozole—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000226	0.00164	CbGpPWpGaD
Anastrozole—Paraesthesia—Epirubicin—urinary bladder cancer	0.000225	0.000469	CcSEcCtD
Anastrozole—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000225	0.00163	CbGpPWpGaD
Anastrozole—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000224	0.000467	CcSEcCtD
Anastrozole—Dyspnoea—Epirubicin—urinary bladder cancer	0.000223	0.000466	CcSEcCtD
Anastrozole—Somnolence—Epirubicin—urinary bladder cancer	0.000223	0.000464	CcSEcCtD
Anastrozole—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000222	0.00161	CbGpPWpGaD
Anastrozole—Anorexia—Doxorubicin—urinary bladder cancer	0.000221	0.000461	CcSEcCtD
Anastrozole—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000221	0.00046	CcSEcCtD
Anastrozole—Dyspepsia—Epirubicin—urinary bladder cancer	0.000221	0.00046	CcSEcCtD
Anastrozole—CYP19A1—Metabolism—UGT2B7—urinary bladder cancer	0.00022	0.0016	CbGpPWpGaD
Anastrozole—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000219	0.000456	CcSEcCtD
Anastrozole—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000218	0.00158	CbGpPWpGaD
Anastrozole—Decreased appetite—Epirubicin—urinary bladder cancer	0.000218	0.000454	CcSEcCtD
Anastrozole—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000216	0.000451	CcSEcCtD
Anastrozole—Fatigue—Epirubicin—urinary bladder cancer	0.000216	0.00045	CcSEcCtD
Anastrozole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000216	0.00157	CbGpPWpGaD
Anastrozole—CYP19A1—Integrated Breast Cancer Pathway—CCND1—urinary bladder cancer	0.000215	0.00156	CbGpPWpGaD
Anastrozole—Constipation—Epirubicin—urinary bladder cancer	0.000214	0.000447	CcSEcCtD
Anastrozole—Pain—Epirubicin—urinary bladder cancer	0.000214	0.000447	CcSEcCtD
Anastrozole—Urticaria—Methotrexate—urinary bladder cancer	0.000213	0.000443	CcSEcCtD
Anastrozole—Body temperature increased—Methotrexate—urinary bladder cancer	0.000212	0.000441	CcSEcCtD
Anastrozole—Abdominal pain—Methotrexate—urinary bladder cancer	0.000212	0.000441	CcSEcCtD
Anastrozole—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000211	0.00044	CcSEcCtD
Anastrozole—Insomnia—Doxorubicin—urinary bladder cancer	0.00021	0.000437	CcSEcCtD
Anastrozole—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000208	0.000434	CcSEcCtD
Anastrozole—CYP19A1—Integrated Breast Cancer Pathway—PTEN—urinary bladder cancer	0.000208	0.00151	CbGpPWpGaD
Anastrozole—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000207	0.000431	CcSEcCtD
Anastrozole—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000206	0.00043	CcSEcCtD
Anastrozole—Somnolence—Doxorubicin—urinary bladder cancer	0.000206	0.00043	CcSEcCtD
Anastrozole—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000205	0.000427	CcSEcCtD
Anastrozole—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000204	0.000425	CcSEcCtD
Anastrozole—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000204	0.00148	CbGpPWpGaD
Anastrozole—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000202	0.00042	CcSEcCtD
Anastrozole—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.0002	0.000417	CcSEcCtD
Anastrozole—Fatigue—Doxorubicin—urinary bladder cancer	0.0002	0.000417	CcSEcCtD
Anastrozole—Urticaria—Epirubicin—urinary bladder cancer	0.000199	0.000415	CcSEcCtD
Anastrozole—Pain—Doxorubicin—urinary bladder cancer	0.000198	0.000413	CcSEcCtD
Anastrozole—Constipation—Doxorubicin—urinary bladder cancer	0.000198	0.000413	CcSEcCtD
Anastrozole—Body temperature increased—Epirubicin—urinary bladder cancer	0.000198	0.000413	CcSEcCtD
Anastrozole—Abdominal pain—Epirubicin—urinary bladder cancer	0.000198	0.000413	CcSEcCtD
Anastrozole—CYP19A1—Metabolism—CYP4B1—urinary bladder cancer	0.000198	0.00144	CbGpPWpGaD
Anastrozole—CYP19A1—Integrated Breast Cancer Pathway—EP300—urinary bladder cancer	0.000198	0.00144	CbGpPWpGaD
Anastrozole—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000197	0.000411	CcSEcCtD
Anastrozole—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000197	0.00143	CbGpPWpGaD
Anastrozole—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000194	0.00141	CbGpPWpGaD
Anastrozole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000194	0.00141	CbGpPWpGaD
Anastrozole—Asthenia—Methotrexate—urinary bladder cancer	0.000192	0.0004	CcSEcCtD
Anastrozole—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000191	0.000398	CcSEcCtD
Anastrozole—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.00019	0.000395	CcSEcCtD
Anastrozole—Pruritus—Methotrexate—urinary bladder cancer	0.000189	0.000395	CcSEcCtD
Anastrozole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000188	0.00137	CbGpPWpGaD
Anastrozole—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000188	0.00137	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism—SLC19A1—urinary bladder cancer	0.000187	0.00136	CbGpPWpGaD
Anastrozole—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000185	0.000385	CcSEcCtD
Anastrozole—Urticaria—Doxorubicin—urinary bladder cancer	0.000184	0.000384	CcSEcCtD
Anastrozole—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000183	0.000382	CcSEcCtD
Anastrozole—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000183	0.000382	CcSEcCtD
Anastrozole—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000183	0.00133	CbGpPWpGaD
Anastrozole—Diarrhoea—Methotrexate—urinary bladder cancer	0.000183	0.000382	CcSEcCtD
Anastrozole—CYP19A1—Metabolism—PRSS3—urinary bladder cancer	0.000182	0.00133	CbGpPWpGaD
Anastrozole—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000181	0.00131	CbGpPWpGaD
Anastrozole—Asthenia—Epirubicin—urinary bladder cancer	0.00018	0.000375	CcSEcCtD
Anastrozole—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.00018	0.00131	CbGpPWpGaD
Anastrozole—Pruritus—Epirubicin—urinary bladder cancer	0.000177	0.00037	CcSEcCtD
Anastrozole—Dizziness—Methotrexate—urinary bladder cancer	0.000177	0.000369	CcSEcCtD
Anastrozole—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000174	0.00127	CbGpPWpGaD
Anastrozole—CYP19A1—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	0.000173	0.00125	CbGpPWpGaD
Anastrozole—Diarrhoea—Epirubicin—urinary bladder cancer	0.000171	0.000357	CcSEcCtD
Anastrozole—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000171	0.000356	CcSEcCtD
Anastrozole—Vomiting—Methotrexate—urinary bladder cancer	0.00017	0.000355	CcSEcCtD
Anastrozole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000169	0.00123	CbGpPWpGaD
Anastrozole—Rash—Methotrexate—urinary bladder cancer	0.000169	0.000352	CcSEcCtD
Anastrozole—CYP19A1—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	0.000169	0.00123	CbGpPWpGaD
Anastrozole—Dermatitis—Methotrexate—urinary bladder cancer	0.000169	0.000352	CcSEcCtD
Anastrozole—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000168	0.00122	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000168	0.00122	CbGpPWpGaD
Anastrozole—Headache—Methotrexate—urinary bladder cancer	0.000168	0.00035	CcSEcCtD
Anastrozole—Asthenia—Doxorubicin—urinary bladder cancer	0.000166	0.000347	CcSEcCtD
Anastrozole—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000166	0.00121	CbGpPWpGaD
Anastrozole—Dizziness—Epirubicin—urinary bladder cancer	0.000166	0.000345	CcSEcCtD
Anastrozole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000165	0.0012	CbGpPWpGaD
Anastrozole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000165	0.0012	CbGpPWpGaD
Anastrozole—Pruritus—Doxorubicin—urinary bladder cancer	0.000164	0.000342	CcSEcCtD
Anastrozole—CYP19A1—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	0.000159	0.00116	CbGpPWpGaD
Anastrozole—Vomiting—Epirubicin—urinary bladder cancer	0.000159	0.000332	CcSEcCtD
Anastrozole—Nausea—Methotrexate—urinary bladder cancer	0.000159	0.000332	CcSEcCtD
Anastrozole—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000159	0.000331	CcSEcCtD
Anastrozole—Rash—Epirubicin—urinary bladder cancer	0.000158	0.000329	CcSEcCtD
Anastrozole—Dermatitis—Epirubicin—urinary bladder cancer	0.000158	0.000329	CcSEcCtD
Anastrozole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000157	0.00114	CbGpPWpGaD
Anastrozole—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000157	0.00114	CbGpPWpGaD
Anastrozole—Headache—Epirubicin—urinary bladder cancer	0.000157	0.000327	CcSEcCtD
Anastrozole—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	0.000157	0.00114	CbGpPWpGaD
Anastrozole—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000156	0.00113	CbGpPWpGaD
Anastrozole—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000154	0.00112	CbGpPWpGaD
Anastrozole—Dizziness—Doxorubicin—urinary bladder cancer	0.000153	0.00032	CcSEcCtD
Anastrozole—Nausea—Epirubicin—urinary bladder cancer	0.000149	0.00031	CcSEcCtD
Anastrozole—Vomiting—Doxorubicin—urinary bladder cancer	0.000147	0.000307	CcSEcCtD
Anastrozole—Rash—Doxorubicin—urinary bladder cancer	0.000146	0.000305	CcSEcCtD
Anastrozole—CYP19A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000146	0.00106	CbGpPWpGaD
Anastrozole—Dermatitis—Doxorubicin—urinary bladder cancer	0.000146	0.000304	CcSEcCtD
Anastrozole—CYP19A1—Metabolism—TYMP—urinary bladder cancer	0.000146	0.00106	CbGpPWpGaD
Anastrozole—Headache—Doxorubicin—urinary bladder cancer	0.000145	0.000303	CcSEcCtD
Anastrozole—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	0.000144	0.00105	CbGpPWpGaD
Anastrozole—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000142	0.00103	CbGpPWpGaD
Anastrozole—CYP19A1—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	0.000142	0.00103	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.00014	0.00102	CbGpPWpGaD
Anastrozole—Nausea—Doxorubicin—urinary bladder cancer	0.000138	0.000287	CcSEcCtD
Anastrozole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000133	0.000964	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism—NAT2—urinary bladder cancer	0.000132	0.000958	CbGpPWpGaD
Anastrozole—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.000121	0.000879	CbGpPWpGaD
Anastrozole—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000119	0.000867	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism—RRM2—urinary bladder cancer	0.000114	0.000827	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	0.000112	0.000816	CbGpPWpGaD
Anastrozole—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000111	0.000807	CbGpPWpGaD
Anastrozole—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00011	0.000796	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	0.000106	0.000774	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—NAT1—urinary bladder cancer	0.000106	0.000774	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism—ENO2—urinary bladder cancer	0.000105	0.000766	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism—HPGDS—urinary bladder cancer	0.000105	0.000766	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000105	0.000761	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000105	0.000761	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism—GSTT1—urinary bladder cancer	0.000102	0.000743	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000101	0.000731	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	9.73e-05	0.000708	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	9.59e-05	0.000697	CbGpPWpGaD
Anastrozole—CYP1A2—urine—urinary bladder cancer	9.37e-05	0.226	CbGeAlD
Anastrozole—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	9.09e-05	0.000661	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—NAT1—urinary bladder cancer	9.09e-05	0.000661	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	8.94e-05	0.00065	CbGpPWpGaD
Anastrozole—CYP2C9—urine—urinary bladder cancer	8.89e-05	0.215	CbGeAlD
Anastrozole—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	8.76e-05	0.000637	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism—NQO1—urinary bladder cancer	8.49e-05	0.000617	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	8.32e-05	0.000605	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	8.28e-05	0.000602	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.24e-05	0.000599	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	8.06e-05	0.000586	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	7.49e-05	0.000544	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	7.4e-05	0.000538	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.18e-05	0.000522	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism—GSTP1—urinary bladder cancer	7.08e-05	0.000515	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	7.07e-05	0.000514	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	7.02e-05	0.00051	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—NAT1—urinary bladder cancer	7.02e-05	0.00051	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	6.89e-05	0.000501	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.85e-05	0.000498	CbGpPWpGaD
Anastrozole—CYP3A4—urine—urinary bladder cancer	6.78e-05	0.164	CbGeAlD
Anastrozole—CYP19A1—Metabolism—TYMS—urinary bladder cancer	6.58e-05	0.000479	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism—NCOR1—urinary bladder cancer	6.51e-05	0.000473	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism—GSTM1—urinary bladder cancer	6.51e-05	0.000473	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.47e-05	0.00047	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—TYMP—urinary bladder cancer	6.45e-05	0.000469	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	6.42e-05	0.000467	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism—GPX1—urinary bladder cancer	6.23e-05	0.000453	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.19e-05	0.00045	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism—ERCC2—urinary bladder cancer	6.12e-05	0.000445	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—NAT2—urinary bladder cancer	5.83e-05	0.000424	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	5.78e-05	0.00042	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism—MTHFR—urinary bladder cancer	5.75e-05	0.000418	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.53e-05	0.000402	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—TYMP—urinary bladder cancer	5.51e-05	0.000401	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	5.46e-05	0.000397	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	5.32e-05	0.000387	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.29e-05	0.000385	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—RRM2—urinary bladder cancer	5.03e-05	0.000366	CbGpPWpGaD
Anastrozole—CYP19A1—prostate gland—urinary bladder cancer	5.02e-05	0.121	CbGeAlD
Anastrozole—CYP1A2—Metabolism—NAT2—urinary bladder cancer	4.98e-05	0.000362	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism—PPARG—urinary bladder cancer	4.66e-05	0.000339	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	4.66e-05	0.000339	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—ENO2—urinary bladder cancer	4.66e-05	0.000339	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.63e-05	0.000337	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	4.52e-05	0.000329	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism—CREBBP—urinary bladder cancer	4.48e-05	0.000326	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.45e-05	0.000324	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—RRM2—urinary bladder cancer	4.3e-05	0.000313	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—TYMP—urinary bladder cancer	4.25e-05	0.000309	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—ENO2—urinary bladder cancer	3.98e-05	0.00029	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	3.98e-05	0.00029	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.96e-05	0.000288	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	3.86e-05	0.000281	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—NAT2—urinary bladder cancer	3.85e-05	0.00028	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.8e-05	0.000277	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—NQO1—urinary bladder cancer	3.76e-05	0.000273	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism—PTGS2—urinary bladder cancer	3.67e-05	0.000267	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.65e-05	0.000265	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—RRM2—urinary bladder cancer	3.32e-05	0.000241	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—NQO1—urinary bladder cancer	3.21e-05	0.000233	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism—PTEN—urinary bladder cancer	3.2e-05	0.000233	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.18e-05	0.000231	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	3.13e-05	0.000228	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.12e-05	0.000226	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.07e-05	0.000223	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.07e-05	0.000223	CbGpPWpGaD
Anastrozole—CYP19A1—Metabolism—EP300—urinary bladder cancer	3.05e-05	0.000222	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.03e-05	0.00022	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.98e-05	0.000217	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.91e-05	0.000212	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.88e-05	0.000209	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.88e-05	0.000209	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.76e-05	0.0002	CbGpPWpGaD
Anastrozole—CYP19A1—female reproductive system—urinary bladder cancer	2.74e-05	0.0661	CbGeAlD
Anastrozole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.72e-05	0.000198	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.71e-05	0.000197	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	2.68e-05	0.000195	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.59e-05	0.000188	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2.54e-05	0.000185	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—TYMS—urinary bladder cancer	2.49e-05	0.000181	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.48e-05	0.00018	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	2.46e-05	0.000179	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	2.46e-05	0.000179	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—GPX1—urinary bladder cancer	2.36e-05	0.000171	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	2.31e-05	0.000168	CbGpPWpGaD
Anastrozole—CYP1A2—renal system—urinary bladder cancer	2.29e-05	0.0553	CbGeAlD
Anastrozole—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	2.17e-05	0.000158	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.07e-05	0.00015	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—PPARG—urinary bladder cancer	2.06e-05	0.00015	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.98e-05	0.000144	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.92e-05	0.00014	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.9e-05	0.000138	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.9e-05	0.000138	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.82e-05	0.000132	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.79e-05	0.00013	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.76e-05	0.000128	CbGpPWpGaD
Anastrozole—CYP2C9—female reproductive system—urinary bladder cancer	1.74e-05	0.0421	CbGeAlD
Anastrozole—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.69e-05	0.000123	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.68e-05	0.000122	CbGpPWpGaD
Anastrozole—CYP3A4—renal system—urinary bladder cancer	1.66e-05	0.04	CbGeAlD
Anastrozole—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.62e-05	0.000118	CbGpPWpGaD
Anastrozole—CYP19A1—lymph node—urinary bladder cancer	1.6e-05	0.0387	CbGeAlD
Anastrozole—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.42e-05	0.000103	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.39e-05	0.000101	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.36e-05	9.9e-05	CbGpPWpGaD
Anastrozole—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.35e-05	9.82e-05	CbGpPWpGaD
Anastrozole—CYP3A4—female reproductive system—urinary bladder cancer	1.33e-05	0.0321	CbGeAlD
Anastrozole—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.31e-05	9.51e-05	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.21e-05	8.8e-05	CbGpPWpGaD
Anastrozole—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.15e-05	8.39e-05	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.07e-05	7.78e-05	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—PTEN—urinary bladder cancer	9.34e-06	6.79e-05	CbGpPWpGaD
Anastrozole—CYP3A4—Metabolism—EP300—urinary bladder cancer	8.9e-06	6.47e-05	CbGpPWpGaD
